NASDAQ:PDLI - PDL BioPharma Stock Price, Forecast & News

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

PDL BioPharma announced that its board has approved a share buyback plan on Monday, September 24th 2018, which allows the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 27.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.

PDL BioPharma Inc (NASDAQ:PDLI) released its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported $0.10 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.04. The biotechnology company had revenue of $46.58 million for the quarter. View PDL BioPharma's Earnings History.

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for PDL BioPharma.

1 brokers have issued twelve-month target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 18.3%. View Analyst Price Targets for PDL BioPharma.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.

News articles about PDLI stock have been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. PDL BioPharma earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for PDL BioPharma.

PDL BioPharma saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 10,150,000 shares, a decrease of 27.3% from the December 31st total of 13,960,000 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is presently 7.7 days. Approximately 9.1% of the shares of the company are sold short. View PDL BioPharma's Current Options Chain.

Some companies that are related to PDL BioPharma include Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Achillion Pharmaceuticals (ACHN), Osiris Therapeutics (OSIR), SIGA Technologies (SIGA), AMAG Pharmaceuticals (AMAG), BioTime (BTX), AVEO Pharmaceuticals (AVEO), Vical (VICL), ImmunoCellular Therapeutics (IMUC) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), Teva Pharmaceutical Industries (TEVA), General Electric (GE), Bank of America (BAC), NovaBay Pharmaceuticals (NBY) and Cara Therapeutics (CARA).

PDL BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.16%), Engine Capital Management LP (5.43%), Brandes Investment Partners LP (5.09%), Connor Clark & Lunn Investment Management Ltd. (3.51%), Charles Schwab Investment Management Inc. (3.04%) and State Street Corp (2.90%). View Institutional Ownership Trends for PDL BioPharma.

PDLI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, UBS Group AG, Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, State Board of Administration of Florida Retirement System, SG Americas Securities LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for PDL BioPharma.

PDLI stock was acquired by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Ancora Advisors LLC, Context Capital Management LLC, AQR Capital Management LLC, Brandes Investment Partners LP, Thrivent Financial for Lutherans, Caxton Associates LP and Bank of Montreal Can. View Insider Buying and Selling for PDL BioPharma.

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PDLI stock can currently be purchased for approximately $3.67.